Aqueous extract of the aerial parts of a plant of the genus Aster and its uses

Abstract

The present invention relates to an aqueous extract obtained from a plant of the genus Aster for cosmetic or therapeutic applications, in particular in the prevention and / or treatment of acne.

Description

Title of the invention: Aqueous extract of the aerial parts of a plant of the genus Aster and its uses Technical field

[0001] The invention relates to an aqueous extract obtained from a plant of the genus Aster for cosmetic or therapeutic applications, in particular in the prevention and / or treatment of acne.

[0002] State of the art

[0003] Acne is a common and chronic inflammatory skin disease of the pilosebaceous system. It affects most adolescents and accounts for more than half of dermatology consultations. It is characterized by hypersecretion of sebum (hyperseborrhea) leading to obstruction of the excretory duct of the pilosebaceous follicle. The obstruction then facilitates the proliferation of bacteria normally present in the skin such as Cutibacterium acnes (C. acnes) or Staphylococcus aureus (S. aureus) bacteria responsible for inflammation and the appearance of red spots. Acne, depending on the severity of the pathology, can cause physical complications but also lead to a certain psychological discomfort.

[0004] The causes of acne are known and diverse. Thus, the genetic and hormonal context and environmental factors, including smoking and pollution, promote inflammation through the production of cytokines. In parallel, the dermal production of antimicrobial peptides and lipids controls skin bacteria, particularly C. acnes and S. aureus.

[0005] The commensal bacterium C. acnes, formerly known as Pro-pionibacterium acnes and also including Propionibacterium avidum and Propioni-bacterium granulosum, is involved in maintaining healthy skin but can also act as an opportunistic pathogen in acne such as acne vulgaris, although Staphylococcus aureus (S. aureus) is also involved in cutaneous acne.

[0006] Until now, the majority of acne treatments have focused on reducing the overproduction of sebum due to hormonal imbalance, reducing the proliferation of C. acnes and S. aureus, and reducing the inflammatory consequences of these infections. However, these treatments mostly target only one aspect of the etiology of acne. In addition, resistance of C. acnes to antibiotic treatments has gradually emerged over the years to become a global problem, with high rates of 21% to 70% of resistance reported for erythromycin (macrolides) and clindamycin (lincosamides) and less frequent resistance to tetracycline (4% to 30%).

[0007] The anti-inflammatory approach in acne has focused mainly on general anti-inflammatory agents which have low specificity and side effects.

[0008] There is therefore a need for a new approach to prevent and treat acne while targeting all of these etiologies and limiting the phenomenon of multi-resistant bacteria. Summary of the invention

[0009] To meet this need, the invention proposes a novel aqueous extract obtained from the aerial parts of a plant of the genus Aster, in particular Aster alpinus and / or Aster tataricus.

[0010] It has recently been shown that C. acnes specifically triggers the release of IL-1 [3, a cytokine involved in the innate immune response (Li et al., Journal of Investigative Dermatology (2014) 134, 2747-2756).

[0011] However, the inventors have discovered that such an extract makes it possible to effectively combat the production of IL-6 stimulated by IL-1 [> by human epithelial cells, as well as to inhibit the proliferation of C. acnes and S. aureus.

[0012] These plants are known mainly in the Mongolian and Chinese pharmacopoeia for oral administration in the treatment of fever and as a cough medicine. In particular, the extracts of these plants as used in the pharmacopoeia are obtained from the root system and after alcoholic or hydroalcoholic extraction.

[0013] Thus, the invention relates to an aqueous extract obtained from the aerial parts of a plant of the genus Aster.

[0014] In particular, the plant can be chosen from Aster alpinus, Aster tataricus, Aster nova-angliae, Aster umbellatus, Aster tongolensis, Aster radula, Aster novi-belgii, Aster macrophyllus, Aster laevis, Aster ericoides, Aster dumosus, Aster ageatoides, Aster frikantii, Aster cordifolius, Aster linosyris, Aster sedifolius, Aster laterifloris, Aster divaricatus, Aster amethystinus, Aster pyraneus, Aster pringlei, Aster sibiricus, Aster radula, Aster amellus and their mixtures.

[0015] Preferably, the extract according to the invention is obtained from the aerial parts of Aster alpinus and / or Aster tataricus.

[0016] According to another object, the invention relates to the extract according to any of the preceding embodiments for its use as a medicament, in particular as an antibiotic and / or anti-inflammatory.

[0017] Preferably, the extract is intended to be used in the prevention and / or treatment of diseases associated with an infection by C. acnes and / or S. aureus, including including multi-resistant forms of C. acnes and / or S. aureus.

[0018] By infection by C. acnes and / or S. aureus, we mean more preferably skin infections by C. acnes and / or S. aureus but also prosthesis infections by C. acnes and / or S. aureus.

[0019] Preferably, the extract according to the invention is intended to be used in the prevention and / or treatment of a disease chosen from acne, psoriasis, vitiligo, acne vulgaris, seborrheic dermatitis and atopic dermatitis.

[0020] According to a preferred embodiment, the extract according to the invention is capable of being obtained by the extraction process comprising the following steps: a. drying and grinding of the aerial parts of the plant, b. aqueous maceration of the aerial parts obtained in step a) at room temperature in the absence of organic solvent, c. filtration of the extract obtained in step b) and d. concentration of the extract obtained in step c).

[0021] According to another object, the invention also relates to such a method for extracting the aqueous extract.

[0022] The invention also relates to a composition comprising the extract according to the invention. Thus, the composition may be pharmaceutical or cosmetic and comprises the extract according to the invention at a concentration greater than or equal to 0.1 mg / ml.

[0023] When it is a cosmetic composition, it comprises the extract according to the invention and at least one cosmetically acceptable excipient. When it is a pharmaceutical composition, it comprises the extract according to the invention and at least one pharmaceutically acceptable excipient.

[0024] Regardless of the use, the composition is in a form suitable for topical application.

[0025] When the composition according to the invention is a pharmaceutical composition, it is intended to be used as a medicament.

[0026] When the composition according to the invention is a cosmetic composition, it is intended to be used as a cosmetic product, that is to say aimed at treating healthy, non-sick people.

[0027] Thus, the invention also relates to the cosmetic uses of the extract or the composition comprising it for its cosmetic effects, in particular for an anti-redness and / or anti-swelling effect or to combat edema.

[0028] Other characteristics and advantages will emerge from the detailed description of the invention, the examples and the figures which follow. Brief description of the Figures

[0029] [Fig.l] represents the anti-inflammatory effect on CACO-2 cells incubated with different extracts. Cells were stimulated with 0.25 ng / ml IL-1[>, except where indicated "without IL-1[3" (C0%), in triplicate. C100% are cells without test sample. The resulting cell supernatants were diluted 1 / 10 directly after sampling and analyzed by ELISA for IL-6. Detailed description of the invention

[0030] Definition

[0031] By "extract" or "aqueous extract" of a plant of the genus Aster within the meaning of the invention, we mean a set of one or more molecules obtained from an extract of the genus Aster, preferably from the aerial parts, according to an aqueous extraction process.

[0032] For the purposes of the invention, the term "aerial parts" means the vegetative apparatus of a plant, including organs such as the stem, buds, leaves, flowers, fruits, preferably the leaves. The term "aerial parts" also means all or part of the aerial parts, i.e. the stem and / or the buds and / or the leaves and / or the flowers and / or possibly the fruits, preferably the leaves.

[0033] For the purposes of the invention, the term "treatment" means the action of reversing, attenuating, inhibiting the progression of or preventing the disorder or condition to which this term applies. Preferably, it means the action of reversing, attenuating, inhibiting the progression of or preventing diseases associated with infection by C. acnes and / or S. aureus, more preferably prosthesis infections by C. acnes and / or S. aureus and / or acne, psoriasis, vitiligo, acne vulgaris, seborrheic dermatitis or atopic dermatitis.

[0034] For the purposes of the invention, the term "healthy subject" means a subject who may be a human being or an animal (other than a human being) not suffering from any pathology associated with an infection by C. acneset / or S. aureus, such as prosthesis infections by C. acneset / or S. aureus, acne, psoriasis, vitiligo, acne vulgaris, seborrheic dermatitis or atopic dermatitis.

[0035] By "medicine" within the meaning of the invention is meant an active ingredient used for therapeutic purposes used alone or combined with other active or non-active substances in medicinal formulas including phytotherapy, intended for humans or animals suffering from a disease such as an infection by C. acneset / or S. aureus.

[0036] Extract according to the invention

[0037] The present invention therefore relates to an aqueous extract obtained from a plant of the genus Aster, in particular an extract obtained from the aerial parts of the plant, more preferably from the leaves. In a particularly preferred manner, the leaves are harvested and then dried before the extraction process.

[0038] Plants of the genus Aster are dicotyledonous plants of the As-teraceae family and include many species. They are native to North America, Europe or the Himalayas. They are perennial plants, hardy with spring, summer or autumn flowering depending on the species. The best known species are Aster alpinus or Alpine Aster which flowers in early summer and Aster tataricus or Tartarian Aster which flowers in autumn.

[0039] Plants are composed of two distinct parts: the aerial part and the root part. The root part is generally hidden underground except in certain epiphytic plants, while the aerial part is visible.

[0040] The roots are divided into several parts. Sometimes they have a swollen part (rhizome, nodules, etc.) and sometimes they are smooth. The main roots are generally large and fleshy and then divide into smaller secondary roots and rootlets that capture nutrients. The roots have two functions: they allow the plant to be anchored in the soil but also to feed itself thanks to the phenomenon of absorption of water and mineral salts contained in the soil.

[0041] The aerial part includes several organs: the stem, the buds, the leaves, the flowers, and possibly the fruits.

[0042] In the context of the invention, the inventors were preferentially interested in the aerial parts of the plant, that is to say all or part of the aerial parts (stem and / or buds and / or leaves and / or flowers and / or possibly fruits), in particular the leaves.

[0043] Thus, from all or part of the aerial parts, and in particular from the leaves, of plants of the genus Aster, the inventors have surprisingly identified that an aqueous extract makes it possible to obtain a biocidal effect, in particular on the bacteria responsible for acne and an anti-inflammatory effect, in particular an anti-IL-1 activity[3.

[0044] According to a particular embodiment, the extract according to the invention is obtained by aqueous maceration, preferably at room temperature, in the absence of organic solvent.

[0045] Preferably, the extract according to the invention is capable of being obtained by the extraction process comprising the following steps: a. drying and grinding of the aerial parts of the plant, b. aqueous maceration of said aerial parts obtained in step a) at room temperature in the absence of organic solvent, c. filtration of the extract obtained in step b) and d. concentration of the extract obtained in step c).

[0046] Optionally, the extraction process comprises an additional drying step after step d) of concentrating the extract. In particular, the drying may be carried out by freeze-drying. The extract according to the invention is then in the form of a powder or an agglomerate.

[0047] Preferably, the extraction is carried out in the absence of organic, alcoholic or hydroalcoholic solvent. The use of such solvents makes it possible to extract toxic substances which are not desirable in the context of the invention. The extract according to the invention aims to be natural, healthy and non-toxic.

[0048] According to another particular embodiment, the extract according to the invention is obtained from a species chosen from Aster alpinus, Aster tataricus, Aster nova-angliae, Aster umbellatus, Aster tongolensis, Aster radula, Aster novi-belgii, Aster ma-crophyllus, Aster laevis, Aster ericoides, Aster dumosus, Aster ageatoides, Aster frikantii, Aster cordifolius, Aster linosyris, Aster sedifolius, Aster laterifloris, Aster di-varicatus, Aster amethystinus, Aster pyraneus, Aster pringlei, Aster sibiricus, Aster radula, Aster amellus and their mixtures.

[0049] Preferably the species is Aster alpinus and / or Aster tataricus.

[0050] According to another object, the invention relates to the extract according to the invention for its use as a medicament.

[0051] According to one embodiment, the drug may be either an antibiotic, or an anti-inflammatory drug, or an antibiotic and anti-inflammatory drug.

[0052] According to a variant, when the extract is used as an antibiotic and / or anti-inflammatory, the extract may be an aqueous extract obtained from a plant of the genus Aster, in particular an extract from the aerial parts and / or the root system of a plant of the genus Aster.

[0053] When the extract comes from the aerial parts and / or the root system of a plant of the Aster genus, the Aster plant is preferably chosen from Aster alpinus, Aster tataricus, Aster nova-angliae, Aster umbellatus, Aster tongolensis, Aster radula, Aster novi-belgii, Aster macrophyllus, Aster laevis, Aster ericoides, Aster dumosus, Aster ageratoides, Aster frikantii, Aster cordifolius, Aster linosyris, Aster sedifolius, Aster laterifloris, Aster divaricatus, Aster amethystinus, Aster pyraneus, Aster pringlei, Aster sibiricus, Aster radula, Aster amellus and their mixtures, more preferably Aster alpinus and / or Aster tataricus.

[0054] According to a preferred embodiment, the extract according to the invention is used in the prevention and / or treatment of diseases associated with an infection by C. acnes and / or S. aureus, including multi-resistant forms of C. acnes and S. aureus.

[0055] The diseases associated with an infection by C. acnes and / or S. aureus are preferentially chosen from skin infections by C. acnes and / or S. aureus and prosthesis infections by C. acnes and / or S. aureus.

[0056] When it is a skin infection by C. acnes and / or S. aureus, the disease is preferentially chosen from acne, psoriasis, vitiligo, acne vulgaris, seborrheic dermatitis and atopic dermatitis.

[0057] Prosthesis infection or periprosthetic infection or prosthetic infection is a rare but dreaded complication because the precise diagnosis is complex. Thus, its management requires collaboration between an orthopedic doctor and an infectious disease specialist. A lack of diagnosis can have serious repercussions, including removal of the prosthesis, or even septicemia. Identifying the germ responsible for the infection is therefore essential. However, infections associated with surgeries aimed at inserting a prosthesis are frequently linked to C. acnes and / or S. aureus (>31%).

[0058] When there is a suspicion of bacterial infection after implantation of a prosthesis, it is therefore of interest to treat it as quickly as possible. This type of infection can be acute or chronic. Acute infection is rapid and can lead to septicemia. However, treatment is fairly well managed by conventional antibiotics.

[0059] Chronic infections are more complex, appear later and are less accessible to conventional antibiotics. Indeed, a biofilm is produced by the bacteria responsible for the infection such as C. acnes making accessibility to antibiotics difficult. However, the production of this biofilm is notably induced by the production of Il-1 [3. There is therefore also an interest in preventing and / or treating prosthesis infections by C. acnes and / or S. aureus.

[0060] Composition according to the invention

[0061] According to another subject, the invention relates to a composition comprising the extract according to the invention, and an ingredient chosen from glycerol or glycerin, alcohol, oil and water. By way of example, for a liquid formulation, the aqueous extract is mixed with glycerin in proportions of between 50 and 80% by weight of glycerin, in order to be microbiologically stabilized.

[0062] When the extract according to the invention is in a dry form, it can be resuspended in a solution chosen from glycerol, alcohol, oil and water.

[0063] The composition according to the invention may be in the form of an aqueous or oily composition, an emulsion or an aqueous bead.

[0064] The composition according to the invention may be presented in a form suitable for topical application, preferably in a form chosen from a cream, a serum, a mask, a balm and a lotion.

[0065] The extract according to the invention included in the composition may be present at a concentration of at least 0.1 mg / ml.

[0066] Preferably, the concentration is less than or equal to 0.9 mg / ml. More preferably, the concentration is between 0.1 mg / ml and 0.9 mg / ml.

[0067] The composition according to the invention, in addition to the extract according to the invention, may comprise other constituents such as one or more other active principle(s) such as, for example, plant extracts comprising antioxidants and / or hyaluronic acid and / or collagen.

[0068] According to a preferred embodiment, the composition according to the invention comprises at least one pharmaceutically acceptable excipient, that is to say an ingredient which is useful in the preparation of a pharmaceutical composition, and which is safe and non-toxic, for pharmaceutical use.

[0069] When the composition according to the invention comprises a pharmaceutically acceptable excipient, it is intended to be used as a medicament.

[0070] According to another embodiment, the composition according to the invention comprises at least one cosmetically acceptable excipient, that is to say which does not cause sensations of discomfort for the user such as redness, tightness or tingling.

[0071] Cosmetically acceptable excipients may be chosen from oils, such as silicone oils, linear or cyclic, volatile or non-volatile or vegetable oils; waxes, such as ozokerite, polyethylene wax, beeswax or camauba wax or vegetable waxes; silicone elastomers; surfactants, preferably emulsifying, whether non-ionic, anionic, cationic or amphoteric; co-surfactants, such as linear fatty alcohols; thickeners and / or gelling agents; humectants, such as polyols like glycerin; colorants, preservatives, fillers; tensors; sequestrants; perfumes; hyaluronic acid; collagen, plant extracts or floral waters.

[0072] When the composition according to the invention comprises a cosmetically acceptable excipient, it aims to be used as a non-therapeutic cosmetic product intended for healthy, non-ill subjects.

[0073] Method

[0074] The extract can be obtained by any aqueous extraction process known to those skilled in the art.

[0075] In particular, the extraction process may comprise the following steps: a. drying and grinding of the aerial parts of the plant, b. aqueous maceration of the aerial parts obtained in step a) at room temperature in the absence of organic solvent, c. filtration of the extract obtained in step b) and d. concentration of the extract obtained in step c).

[0076] Advantageously, said method can be carried out at room temperature. Preferably, the method does not comprise an extraction step comprising the addition of an alcoholic or hydroalcoholic solution.

[0077] The extract is then obtained in liquid form. When the extract is in solid form, the process further comprises a freeze-drying step.

[0078] Thus, the extract can be in liquid form or in solid form.

[0079] Cosmetic use

[0080] According to another subject, the invention relates to a cosmetic use of an extract according to the invention or of a composition according to the invention for a cosmetic effect, in particular an anti-redness and / or anti-swelling effect and / or for combating edema.

[0081] The cosmetic effects are notably chosen from an anti-redness, anti-swelling, purifying, cleansing effect, to combat edema, to reduce skin imperfections, to improve the quality of the skin, to reduce comedones, to reduce blackheads and to reduce the oily skin effect.

[0082] The invention is now illustrated by non-limiting examples of compositions according to the invention and by results. Examples

[0083] Example 1 - Extract of Aster alpinus according to the invention

[0084] The extract is obtained by the extraction process described below. The process comprises the following steps: a. drying and grinding of the aerial parts of the plant, b. aqueous maceration of the aerial parts obtained in step a) at room temperature in the absence of organic solvent, c. filtration of the extract obtained in step b) and d. concentration of the extract obtained in step c).

[0085] The extract obtained is then in the form of an aqueous extract including in particular sugars and flavonoids.

[0086] Example 2 - Extract of Aster tataricus according to the invention

[0087] The extract is obtained by the process described in example 1. The extract obtained is then in the form of an aqueous extract comprising in particular sugars and flavonoids.

[0088] Example 3 - Extract according to the invention in solid form

[0089] The extract is obtained according to the process described in Example 1 or 2 and comprises a final additional step of drying by freeze-drying to obtain either an extract of Aster alpinus in solid form, or an extract of Aster tataricus in solid form.

[0090] Example 3

[0091] Test on the antibacterial effect of an extract according to the invention and outside the invention

[0092] The test aims to compare the effectiveness of an extract according to Example 1 or Example 2 and an extract of the genus Aster obtained from the root system (Outside the Invention). The test aims to identify the minimum inhibitory concentration (MIC) on a strain of S. aureus deposited under number DSM799.

[0093] The minimum inhibitory concentration (MIC) was determined in vitro using the culture of S. aureus in solution in 96-well plates. The initial concentration of S. aureus was 1.25*10A5 CFU / ml. After 48h of incubation in the presence of a series of dilutions of the extract, a 20μl drop was taken and placed on a TSB agar plate. The diameter of the "drop culture" is approximately 1.5 cm. The agar plate cultures were then incubated at 37°C for 14 hours.

[0094] The positive control corresponds to the maximum growth of a bacterium, i.e. when it is completely confluent, meaning that the colonies of bacteria stick together and none are visible. Different extracts according to the invention and outside the invention at different concentrations are thus compared. When no colonies, or separate individual colonies, are visible, then the bacteria have been inhibited by the extract. The concentration of the extract is then defined as MIC.

[0095] Results

[0096] Solid extracts according to Example 3 were used for this test. The extracts were diluted by one-third. For each extract, the following concentrations were tested: 8.3 mg / ml, 2.8 mg / ml, 0.9 mg / ml, 0.3 mg / ml and 0.1 mg / ml.

[0097] The results are presented in Table 1 below.

[0098] [Tables 1] MIC [mg / ml] Number of colonies Chloramphenicol 0.05 0 1) Aster alpinus - aerial parts, (Example 1) 0.9 0 2) Aster alpinus - roots, (Not Invention) 2.8 0 3) Aster tataricus - aerial parts, (Example 2) 0.9 0 4) Aster tataricus - roots, (Not Invention) 8.3 0

[0099] The numbers in the table (in mg / ml) indicate the Minimal Inhibitory Concentrations (MIC). The definition of MIC is as follows: Arbitrary units of bacterial growth were determined by agar culture plates (drop method). Cultures where the number of colonies was reduced from confluence (maximal growth) to observable individual colonies were defined as MIC.

[0100] The results show that the extract of Aster alpinus obtained from the aerial parts and the extract of Aster tataricus obtained from the aerial parts have a strong inhibitory effect on S. aureus. Conversely, extracts obtained from the roots of Aster alpinus and Aster tataricus have a weak effect. The MIC was 0.9 mg / ml for both extracts when tested on S. aureus and 0.3 mg / ml for both extracts when tested on C. acnes. Therefore, the origin of the plant is an essential characteristic of the extract to obtain such an effect.

[0101] Test of the anti-inflammatory effect of an extract according to the invention and outside the invention

[0102] The test aims to compare the efficacy of an extract according to Example 1 or Example 2 and an extract of the genus Aster obtained from the root system (Outside the Invention). The test aims to evaluate the anti-inflammatory effect on IL-1 [> on human endothelial cells Caco-2.

[0103] Extracts according to the invention in solid form were used for this test. The extracts in solid form were dissolved in a medium (containing penicillin and streptomycin) using a vortex and were incubated for approximately 1 hour at 37°C. A series of 1 / 3 dilutions was then prepared. For each extract, the following concentrations were tested: 8.3 mg / ml, 2.8 mg / ml, 0.9 mg / ml, 0.3 mg / ml and 0.1 mg / ml. The Caco-2 (P60) cells were at 60% confluence at the start of the test. After 24 hours of incubation of the cells with the extracts, 80 μl had been transferred to a fresh 96-well intermediate plate and centrifuged. The supernatant was then diluted 1 / 10 on the second intermediate plate and then transferred to the coated ELISA plate to measure IL-6 content.

[0104] Results

[0105] The aerial parts of Aster alpinus and Aster tataricus inhibited, in a concentration-dependent manner, IL-1 [3-stimulated IL-6 secretion, with an IC50 of 0.2 mg / ml for both extracts. For Aster tataricus roots, IC50 was higher and close to 0.9 mg / ml, indicating that the root extract is less active than the aerial parts extract. The concentrations that inhibited 50% of IL-1 [3-induced IL-6 production were 0.14 mg / ml for the Aster tataricus extract and 0.3 mg / ml for the Aster alpinus extract.

[0106] Thus, the extracts obtained from the aerial parts make it possible to obtain an anti-inflammatory effect.

Claims

Claims

1. Aqueous extract obtained from a plant of the species Aster alpinus and / or Aster tataricus, characterized in that it is an extract obtained from the aerial parts of the plant.

2. Extract according to the preceding claim, characterized in that the aerial parts are the leaves.

3. Extract according to one of the preceding claims, characterized in that the extract is obtained by aqueous maceration at room temperature.

4. Extract according to one of the preceding claims, obtainable by the extraction process comprising the following steps: a. drying and grinding of the aerial parts of the plant, b. aqueous maceration of the aerial parts obtained in step a) at room temperature in the absence of organic solvent, c. filtration of the extract obtained in step b) and d. concentration of the extract obtained in step c).

5. Extract according to the preceding claim, characterized in that the extraction is carried out in the absence of alcoholic or hydroalcoholic solvent.

6. Extract according to one of the preceding claims for its use as a medicament.

7. Extract for its use according to the preceding claim, as an antibiotic and / or anti-inflammatory.

8. Extract for use according to one of claims 6 or 7, in the prevention and / or treatment of diseases associated with infection by C. acnes and / or S. aureus.

9. Extract for use according to one of claims 6 to 8, wherein the diseases associated with an infection by C. acneset / or S.aureus are chosen from skin infections by C. acneset / or S.aureus and prosthesis infections by C. acneset / or S.aureus.

10. Extract for its use according to one of claims 6 to 9, in the prevention and / or treatment of a disease chosen from acne, psoriasis, vitiligo, acne vulgaris, seborrheic dermatitis and atopic dermatitis.

11. An aqueous extract obtained from a plant of the genus Aster for use in the prevention and / or treatment of diseases associated with an infection with C. acnes and / or S. aureus.

12. Extract for its use according to the preceding claim, characterized in that the aqueous extract is obtained from a species chosen from Aster alpinus, Aster tataricus, Aster nova-angliae, Aster umbellatus, Aster tongolensis, Aster radula, Aster novi-belgii, Aster macrophyllus, Aster laevis, Aster ericoides, Aster dumosus, Aster ageratoides, Aster frikantii, Aster cordifolius, Aster linosyris, Aster sedifolius, Aster late-rifloris, Aster divaricatus, Aster amethystinus, Aster pyraneus, Aster pringlei, Aster sibiricus, Aster radula, Aster amellus and mixtures thereof.

13. Composition comprising the extract according to one of claims 1 to 5 and glycerol and alcohol and water.

14. Composition according to the preceding claim, characterized in that the concentration of the extract is at least 0.1 mg / ml.

15. Composition according to claim 13 or 14 also comprising at least one pharmaceutically acceptable excipient or at least one cosmetically acceptable excipient.

16. Composition according to the preceding claim, in a form suitable for topical application.

17. Composition according to one of claims 13 to 16, characterized in that it is presented in a form chosen from a cream, a serum, a mask and a lotion.

18. Composition according to one of claims 13 to 17 for its use as a medicament.

Images